Current issue
Volume 53, Issue 4, 2025
Online ISSN: 2560-3310
ISSN: 0350-8773
Volume 53 , Issue 4, (2025)
Published: 30.06.2025.
Open Access
All issues
Contents
01.01.2009.
Professional paper
INCIDENCE OF STRESS-ULCЕR IN SEPTIC PATIENTS
Serious metabolic diseases and infections, such as sepsis, may lead to the occurrence of stress ulcers. Unfortunately, in our hospitals, the stress ulcer is often diagnosed as a separate disease, not as the manifestation of the existing stress status of the patient. Therefore, the goal of this pilot study was to establish the incidence of stress ulcers in sepsis patients treated at the Infective Disease Clinic. Patients treated at the Military Medical Academy Infective Disease Clinic during 4 month period, who experienced acute bleeding, verified gastroscopically, were subjected to retrospective analysis. Five out of 344 hospitalized patients had serious hemorrhages. Out of a total of 21 patients diagnosed with bacterial sepsis, acute gastric bleeding was verified gastroscopically in three, or 14.28 percent. To obtain more data, prospective long-term study, wich would include greater number of septic patients, should be conducted.
S. Janićijević-Hudomal, J. Rašić, D. Mikić, V. Piperski
01.01.2008.
Professional reviews
+Gz ACCELERATION AS DINAMIC STRESS
+Gz acceleration is unique dynamic stress to organism. Development of this occurrence depends not only to magnitude of acceleration but to onset rate and duration too. The most of former researches pointed to +Gz stress as significant stress to basic physiological mechanisms like cardiovascular and respiratory system. The new study was to examine responses of neuroendocrine and immune system to +Gz stress.
S. Janićijević-Hudomal, G. Arsić-Komljenović, D. Mikić, J. Kenić
01.12.2008.
Professional paper
ANTIOXIDATIVE POTENCY OF PLANT MELLITIS MELISOPHYLLUM
One of the paradoxes of life on the Earth is that, on one side, oxygen is necessary for living of aerobic organisms. On the other side, increased contrencations of oxygen and especially its reactive metabolites (reactive oxygen species) may lead to the development of number diseases such as Alzheimer, Parkinson, ischemia-reperfusion injury, coronary atherosclerosis, diabetes mellitus, hypertension, and cancer genesis, as well as in the aging process (1, 2,3). Amajor source of free radicals in biological systems is molecular oxygen (O2). By interacting with fundamental cell structures and biomolecules, reactive oxygen species (ROS) can lead to the development of many pathophysiological disorders (4,5). Active principles from plant family Lamiaceae (flavonoids and phenolic compounds, polyphenols), like plant Mellitis melisophillum, may act as new potential antioxidants.
S. Janićijević-Hudomal, J. Kenić, G. Arsić-Komljenović
01.01.2007.
Professional paper
EDICINAL MEDICINAL FEATURES OF TURES OF OLIVE LEAF OLIVE LEAF (Olea europaea Olea europaea L.)
Interest in the olive leaf and its chemical constituents has recently been increasing. Its benefits, however, have been known for centuries, and it has been traditionally used to prevent and treat diseases. The main constituent of the olive leaves is oleuropeine one of iridoide monoterpenes, which is thought to be responsible for pharmacological effects. Furthermore, the olive leaves contain triterpenes including oleanolic and maslinic acid, flavonoides (luteolin, apigenine, rutin...), and chalcones (olivin, olivin-diglucoside). Its chemical content makes olive leaf one of the most potent natural antioxidant. Olive leaf is used to enhance the immune system, as an antimicrobial and in heart disease. Folk medicine uses also include hypertonia, arteriosclerosis, rheumatism, gout, diabetes mellitus, and fever. Recently, experimental animal studies have demonstrated hypoglycemic, hypotensive, antiarrhythmic, and vasodilator effects, as well as spasmolytic effect on the intestinal smooth muscle. Antibacterial, antiviral and antiinflammatory activity were also confirmed. The beneficial properties of olive leaf are further enhanced by the bioavailability of its polyphenolic constituents, which are readily absorbed through the gastrointestinal tract, resulting in significant levels in the circulation. Clinical studies to confirm experimental results are needed
D. Dekanski, S. Janićijević-Hudomal
01.12.2007.
Professional paper
EFFICACY OF PLANT KINGDOM ON STRESS - ULCER DEVELOPING
Despite progress in conventional pharmacology in producing effective drugs, the plant kingdom might provide a useful source of new anti-ulcer compounds for development pharmaceutical entities or, alternatively, as simple dietary adjuncts to existing therapies. Botanical compounds with anti-ulcer activity include flavonoids(i.e.quercetin, naringin, silymarin, anthocyanosides, sophoradin derivatives) saponins (i.e. from Panax japonicus and Kochia scoparia), tannins (i.e. from Linderae umbellatae), gums and mucilages (i.e. gum guar and myrrh). This article reviews the gastro-protective and anti-ulcer properties of the most commonly employed herbal medicines and their identified active constituents. Among herbal drugs, liquorice, aloe gel and capsicum (chilli) have been used extensively and their clinical efficacy documented, but тhe documented literature has centred primarily on pharmacological action in experimental animals.
S. Janićijević-Hudomal, D. Dekanski, J. Rašić
01.01.2006.
Professional reviews
MONITORING THE ADVERSE ADVERSE DRUG REACTIONS REACTIONS TODAY
One the of most importante charactersistics of drug is a drug safety. However, there is no absolute safety. Medicines are troughly tested in controlled clinical trials with limiting population and short duration. Experience has shown that much of our knowledge about a medicine becomes available during the subsequent prescribing practice. Therefore there is a need for continued monitoring medicines after granting of product licence for a new drug (phrmacovigilance). WHO international system for drug safety monitoring as maintained by the Upsala Monitoring Centre (UMC) in Sweden, has built up vastedatabase of reports of suspect adverse drug reactions, coming from national centres in 75 countries in all of the world. The international system products valuable information from countries around the world, to support regulatory follow-up and decision-making. Emphasis is on those signals that may remain at the national level, because of small numbers or absence of local reports. The aim of the WHO's international pharmacovigilance program is a safe and rational medicines evrywhere. In Serbia as of 2005. National Medical Devices Agency is acting on behalf of the Ministry of Health as National Centre for Adverse Drug Reactions. The form for reporting adverse effects of medicines, in both pre-marketing and post-marketing phase can be found and downloaded in Word format on the Agency`s web site www.alims.sr.gov.yu.
S. Janićijević-Hudomal, J. Rašić, R. Mitić, Z. Stanojević
01.12.2006.
Professional reviews
THE USE OF THE USE OF ANTITUBERCULOSIS DRUGS (A ANTITUBERCULOSIS DRUGS (ATD) TODAY
The World Health Organization (WHO) declared tuberculosis (TB) a global emergensy in recognition of its growing importance as public health problem. In response to this situation WHO in 1990 was developed new strategy and framework for effective TB control, wich was called „DOTS“. The aims of treatment of TB are: to cure the pation of TB, to prevent death from active TB or its late effects, to prevent relapse of TB, to decrease transmission of TB to others, and to prevent
the development of acqured drug resistance. Antituberculosis drugs (ATD) are antibiotics and synthetic drugs used in the
treatment of tuberculosis and other deases caused by microorganisms of the genus Mycobacterium. The essential ATD are:
isoniazid (H), rifampicin (R), pyrazinamid (Z), streptomycin (S), ethambutol (E), and thioacetazone (T). The reserve ATD
are: amikacin (Am), kanamycin (Km), capreomycin (Cm), ciprofloxacin (Cx), ofloksacin (O), cycloserine (Cs), ethionamide (Et), protionamide (Pt), and p-aminosalycilic acid (PAS). The regimen recommended for each patient depends on the
diagnostic category for each patient. There are several possible regimens. ATB treatment regimens consists of two phases:
an initial phase and a continuation phase
J. Rašić, S. Janićijević-Hudomal, D. Radišić, Z. Bukumirić, Z. Stanojević